Literature DB >> 22435856

Prognostic value and agreement of achieving lactate clearance or central venous oxygen saturation goals during early sepsis resuscitation.

Michael A Puskarich1, Stephen Trzeciak, Nathan I Shapiro, Ryan C Arnold, Alan C Heffner, Jeffrey A Kline, Alan E Jones.   

Abstract

OBJECTIVES: Lactate clearance (LC) and central venous oxygen saturation (ScvO(2)) have been proposed as goals of early sepsis resuscitation. The authors sought to determine the agreement and prognostic value of achieving ScvO(2) or LC goals in septic shock patients undergoing emergency department (ED)-based early resuscitation.
METHODS: This was a preplanned analysis of a multicenter ED randomized controlled trial of early sepsis resuscitation targeting three variables: central venous pressure, mean arterial pressure, and either ScvO(2) or LC. Inclusion criteria included suspected infection, two or more systemic inflammation criteria, and either systolic blood pressure of <90 mm Hg after intravenous fluid bolus or lactate level of >4 mmol/L. Both ScvO(2) and LC were measured simultaneously. The ScvO(2) goal was defined as ≥70%. Lactate was measured at enrollment and every 2 hours until the goal was reached or up to 6 hours. LC goal was defined as a decrease of ≥10% from initial measurement. The primary outcome was in-hospital mortality.
RESULTS: A total of 203 subjects were included, with an overall mortality of 19.7%. Achievement of the ScvO(2) goal only was associated with a mortality rate of 41% (9/22), while achievement of the LC goal only was associated with a mortality rate of 8% (2/25; proportion difference = 33%; 95% confidence interval [CI] = 9% to 55%). No agreement was found between goal achievement (κ = -0.02), and exact test for matched pairs demonstrated no significant difference between discordant pairs (p = 0.78).
CONCLUSIONS: No agreement was found between LC and ScvO(2) goal achievement in early sepsis resuscitation. Achievement of a ScvO(2) ≥ 70% without LC ≥ 10% was more strongly associated with mortality than achievement of LC ≥ 10% with failure to achieve ScvO(2) ≥ 70%.
© 2012 by the Society for Academic Emergency Medicine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22435856      PMCID: PMC3313083          DOI: 10.1111/j.1553-2712.2012.01292.x

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  16 in total

1.  Early goal-directed therapy in the treatment of severe sepsis and septic shock.

Authors:  E Rivers; B Nguyen; S Havstad; J Ressler; A Muzzin; B Knoblich; E Peterson; M Tomlanovich
Journal:  N Engl J Med       Date:  2001-11-08       Impact factor: 91.245

Review 2.  Central venous oxygen saturation monitoring in the critically ill patient.

Authors:  E P Rivers; D S Ander; D Powell
Journal:  Curr Opin Crit Care       Date:  2001-06       Impact factor: 3.687

3.  Prospective external validation of the clinical effectiveness of an emergency department-based early goal-directed therapy protocol for severe sepsis and septic shock.

Authors:  Alan E Jones; Anne Focht; James M Horton; Jeffrey A Kline
Journal:  Chest       Date:  2007-06-15       Impact factor: 9.410

4.  Early changes in organ function predict eventual survival in severe sepsis.

Authors:  Mitchell M Levy; William L Macias; Jean-Louis Vincent; James A Russell; Eliezer Silva; Benjamin Trzaskoma; Mark D Williams
Journal:  Crit Care Med       Date:  2005-10       Impact factor: 7.598

5.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

6.  Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial.

Authors:  Alan E Jones; Nathan I Shapiro; Stephen Trzeciak; Ryan C Arnold; Heather A Claremont; Jeffrey A Kline
Journal:  JAMA       Date:  2010-02-24       Impact factor: 56.272

7.  Implementation and outcomes of the Multiple Urgent Sepsis Therapies (MUST) protocol.

Authors:  Nathan I Shapiro; Michael D Howell; Daniel Talmor; Dermot Lahey; Long Ngo; Jon Buras; Richard E Wolfe; J Woodrow Weiss; Alan Lisbon
Journal:  Crit Care Med       Date:  2006-04       Impact factor: 7.598

Review 8.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.

Authors:  R C Bone; R A Balk; F B Cerra; R P Dellinger; A M Fein; W A Knaus; R M Schein; W J Sibbald
Journal:  Chest       Date:  1992-06       Impact factor: 9.410

9.  Translating research to clinical practice: a 1-year experience with implementing early goal-directed therapy for septic shock in the emergency department.

Authors:  Stephen Trzeciak; R Phillip Dellinger; Nicole L Abate; Robert M Cowan; Mary Stauss; J Hope Kilgannon; Sergio Zanotti; Joseph E Parrillo
Journal:  Chest       Date:  2006-02       Impact factor: 9.410

10.  Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003.

Authors:  Viktor Y Dombrovskiy; Andrew A Martin; Jagadeeshan Sunderram; Harold L Paz
Journal:  Crit Care Med       Date:  2007-05       Impact factor: 7.598

View more
  30 in total

1.  Venous-to-arterial carbon dioxide difference: an experimental model or a bedside clinical tool?

Authors:  Morten Hylander Møller; Maurizio Cecconi
Journal:  Intensive Care Med       Date:  2015-12-17       Impact factor: 17.440

2.  Prognostic value of central venous oxygen saturation and blood lactate levels measured simultaneously in the same patients with severe systemic inflammatory response syndrome and severe sepsis.

Authors:  Ju-Hee Park; Jinwoo Lee; Young Sik Park; Chang-Hoon Lee; Sang-Min Lee; Jae-Joon Yim; Young Whan Kim; Sung Koo Han; Chul-Gyu Yoo
Journal:  Lung       Date:  2014-02-19       Impact factor: 2.584

3.  The Japanese guidelines for the management of sepsis.

Authors:  Shigeto Oda; Mayuki Aibiki; Toshiaki Ikeda; Hitoshi Imaizumi; Shigeatsu Endo; Ryoichi Ochiai; Joji Kotani; Nobuaki Shime; Osamu Nishida; Takayuki Noguchi; Naoyuki Matsuda; Hiroyuki Hirasawa
Journal:  J Intensive Care       Date:  2014-10-28

4.  Overview of progresses in critical care medicine 2012.

Authors:  Wei Huang; Xianyao Wan
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

Review 5.  Etiology and therapeutic approach to elevated lactate levels.

Authors:  Lars W Andersen; Julie Mackenhauer; Jonathan C Roberts; Katherine M Berg; Michael N Cocchi; Michael W Donnino
Journal:  Mayo Clin Proc       Date:  2013-10       Impact factor: 7.616

6.  Whole blood lactate kinetics in patients undergoing quantitative resuscitation for severe sepsis and septic shock.

Authors:  Michael A Puskarich; Stephen Trzeciak; Nathan I Shapiro; Andrew B Albers; Alan C Heffner; Jeffrey A Kline; Alan E Jones
Journal:  Chest       Date:  2013-06       Impact factor: 9.410

7.  EMS patients and walk-in patients presenting with severe sepsis: differences in management and outcome.

Authors:  Jon Femling; Steven Weiss; Eric Hauswald; David Tarby
Journal:  South Med J       Date:  2014-12       Impact factor: 0.954

8.  Early postictal serum lactate concentrations are superior to serum creatine kinase concentrations in distinguishing generalized tonic-clonic seizures from syncopes.

Authors:  Oliver Matz; Jan Heckelmann; Sebastian Zechbauer; Jens Litmathe; Jörg C Brokmann; Klaus Willmes; Jörg B Schulz; Manuel Dafotakis
Journal:  Intern Emerg Med       Date:  2017-09-12       Impact factor: 3.397

9.  Protocolized Treatment Is Associated With Decreased Organ Dysfunction in Pediatric Severe Sepsis.

Authors:  Fran Balamuth; Scott L Weiss; Julie C Fitzgerald; Katie Hayes; Sierra Centkowski; Marianne Chilutti; Robert W Grundmeier; Jane Lavelle; Elizabeth R Alpern
Journal:  Pediatr Crit Care Med       Date:  2016-09       Impact factor: 3.624

10.  Lactate clearance for assessing response to resuscitation in severe sepsis.

Authors:  Alan E Jones
Journal:  Acad Emerg Med       Date:  2013-07-23       Impact factor: 3.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.